VASCULAR
hamburger
product photo

XIENCE ALPINE OFFERS SOLUTIONS FOR TODAY'S COMPLEX CHALLENGES

  • Provides peak performance in increasingly complex lesions
    • Delivery system specifically designed for high performance in complex anatomy
  • Improves clinical outcomes
    • The Safety of XIENCE for complex patients

ENGINEERED FOR COMPLEX INTERVENTION FROM TIP TO HUBxience

Tests performed by and data on file at Abbott Vascular

XIENCE SAFETY

xience

Sources:  1BMS is a composite of several bare metal stents as a representation of the BMS category.  2 An odds ratio is a method of comparing the odds of an event between two groups. 3 A rate ratio was calculated instead of an odds ratio.  4 Median follow-up was 1.9 years in this study.  5Median follow-up was 2.2 years in this study.  6 Palmerini T, et al. The Lancet. March 23, 2012; 379:1393-1402. 7 Bangalore S, et al. Circulation May 14, 2012;125:2873-2891. 8 Bangalore S, et al. British Medical Journal, Aug 10, 2012. 345:e5170 doi: 10.1136/bmj.e5170. 9 Palmerini T, et al. JACC. June 7, 2013;62:496-504.  10 Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/ circinterventions. 113.000415. *Trials focused on specific patient subsets including AMI, STEMI, CTO, diabetics, bifurcation and other complex lesions 

xience

Source: Valgimigli, M, Effects of Cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014.
*BMS is a composite of several bare metal stents as a representation of the BMS category **44% STEMI, 19% diabetes, mean age of 67.

xience

Sources: 1Bangalore S, et al. BMJ, Nov 2013. 347:f6625 doi: 10.1136/bmj.f6625. 2Palmerini T et al. JACC Nov 2013 doi: 10.1016/j.jacc.2013.09.061.3A rate ratio is a method of comparing the incidence of events between two groups. 4An odds ratio is a method of comparing the odds of an event between two groups.

"Meta-analyses should be regarded as hypothesis-generating and the findings of Palmerini and colleagues suggest that a randomized trial of CoCr EES and BMS is desirable." Ormiston, The Lancet, April 2012
The XIENCE system’s clinical outcomes result from its components, including: a thin-strut, flexible ring and link design, with favorable strut apposition, no metal-to-metal touch points, and low strain upon expansion; the novel Everolimus compound; and the multi-layer coating and primer technologies, using a fluorinated polymer class known for cardiovascular implants, and known for having excellent mechanical properties.
Note: The above charts are illustrative representation of various odds ratios from the sourced meta-analyses.
Note: XIENCE has demonstrated reduced event rates in the safety endpoints of stent thrombosis, death and MI versus several BMS and BP-DES in multiple large scale meta-analyses. Sources: Dr. Valgimigli, EuroPCR 2014; Palmerini et al. Lancet. 2012;379:1393-402; Bangalore et al. Circulation 2012;125:2873-2891

PART NUMBERS AND ORDERING INFORMATIONxience image

AP2941159-WBO Rev. B

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

YESNO